Worst ASX 20 shares of the past year: CSL (ASX:CSL) makes the cut

These ASX 20 shares were the laggards of the past year…
The post Worst ASX 20 shares of the past year: CSL (ASX:CSL) makes the cut appeared first on The Motley Fool Australia. –

The S&P/ASX 20 Index (ASX: XTL) comprises the 20 biggest companies on the Australian Securities Exchange. While the concentrated index performed solidly over the past year, returning 26.9% before dividends – not all of its constituents enjoyed the same performance.

In light of this, we take a moment to evaluate the three worst-performing shares in the ASX 20 over the past year.

Heading off road

Although it has inched out a positive return over the past year, Transurban Group (ASX: TCL) is still the third-worst performing share of the ASX 20. The Australian and United States toll road operator has climbed 6.3% during the past 12 months.

Looking at the 1-year chart, we can see that shareholders have endured a bumpy ride during the period. It appears the share price took a hit during November and December. Around this time the company provided a traffic update, indicating traffic had increased during October and November despite the ongoing impacts of COVID-19.

However, in February Transurban released its first-half results for FY21. These results informed investors of a 16.6% fall in revenue to $1,165 million and a 17.8% decrease in average daily traffic across its portfolio.

Volatility for this ASX 20 share

Well-known blue-chip share, CSL Limited (ASX: CSL) has stumbled during the past 12 months. Australia’s third-largest company by market capitalisation shaved off 1.3% over the past year.

COVID-19 has produced headwinds for the Australian-based biotherapeutics giant. Firstly, plasma collections have been impacted by restrictions induced by the pandemic. CSL relies on these collections for many of its leading therapies.

Secondly, the company’s growth in treatment sales has been tempered by a reduction in doctor visits.

More recently, investors may have become concerned about a leading broker’s take on CSL’s Seqirus vaccine business. According to Goldman Sachs, the rapid development of new vaccines using mRNA could disrupt the company’s seasonal flu market in the future.

Not so golden performance

Finally, the worst-performing share in the ASX 20 Index is gold mining company – Newcrest Mining Ltd (ASX: NCM). The $21 billion miner wiped nearly 23% off its share price in the past year.

In short, Newcrest is the victim of the falling gold price. The value of the precious commodity has tarnished ~7% since this time last year. However, Newcrest has managed to increase both its revenue and earnings during this time.

According to its FY21 half-year results, revenue jumped 21% to $2,172 million compared to the prior corresponding period. Additionally, statutory profit skyrocketed 134% to $553 million.

The post Worst ASX 20 shares of the past year: CSL (ASX:CSL) makes the cut appeared first on The Motley Fool Australia.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the five best ASX stocks for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now.

*Returns as of May 24th 2021

More reading

Why this sector is lifting the ASX 200 higher today

ASX 200 Weekly Wrap: COVID wobbles ASX as shares retreat

3 ASX 200 blue chip shares analysts rate highly

5 things to watch on the ASX 200 on Monday

Is the CSL (ASX:CSL) vaccine business under threat?

Motley Fool contributor Mitchell Lawler has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;

To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.

An active and funded account with a positive trading balance is required to continue to have access to the tools;

Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;

Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!